Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
Academic Article
Overview
MeSH Major
Antibodies, Monoclonal
Lutetium
Prostate-Specific Antigen
Prostatic Neoplasms
Radioisotopes
abstract
The MTD of (177)Lu-J591 is 70 mCi/m(2). Multiple doses of 30 mCi/m(2) are well tolerated. Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation.